Medical Oncology

, Volume 25, Issue 1, pp 110–112

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor

  • Hasan Şenol Coşkun
  • Sema Sezgin Göksu
  • Mehmet Şahin
  • Güçhan Alanoğlu
CASE

DOI: 10.1007/s12032-007-0053-5

Cite this article as:
Coşkun, H.Ş., Göksu, S.S., Şahin, M. et al. Med Oncol (2008) 25: 110. doi:10.1007/s12032-007-0053-5

Abstract

Imatinib is now indicated as the first line therapy for chronic myeloid leukemia (CML). Treatment of CML with imatinib is generally well tolerated and the risk of severe adverse affects is low. Many new drugs including targeted therapy are combined with antineoplastic agents safely. We here report a patient with CML who developed concurrent mesenchymal tumor while undergoing therapy with imatinib and treated with combination chemotherapy including bleomycin, etoposide, and cisplatin, as well as imatinib without severe toxicity.

Keywords

CML Imatinib Combination chemotherapy 

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Hasan Şenol Coşkun
    • 1
    • 2
    • 3
  • Sema Sezgin Göksu
    • 1
    • 2
    • 3
  • Mehmet Şahin
    • 1
    • 2
    • 3
  • Güçhan Alanoğlu
    • 1
    • 2
    • 3
  1. 1.Medical Faculty, Department of Medical OncologySüleyman Demirel UniversityIspartaTurkey
  2. 2.Medical Faculty, Department of HematologySüleyman Demirel UniversityIspartaTurkey
  3. 3.Medical Faculty, Department of ImmunologySüleyman Demirel UniversityIspartaTurkey

Personalised recommendations